Skyepharma PLC (LSE SKP), the expert oral and inhalation drug delivery company, today announces that it has acquired the global rights and related intellectual property (including granted patents and patent applications) to a novel inhaled therapy platform from Pulmagen Therapeutics (Synergy) Limited ("Pulmagen").